5 Key Takeaways
-
1
In a Phase 1 study of healthy volunteers, subcutaneous VRDN-008 produced a peak IgG reduction of 74%, maintained for up to 8 weeks.
-
2
VRDN-008 had a reported half-life of 15 to 18 days, approximately six times longer than first-generation Fc fragments.
-
3
The therapy was generally well tolerated, with no serious adverse events or dose-limiting toxicities and no reductions in albumin or LDL cholesterol.
-
4
Viridian plans to begin a pivotal trial in myasthenia gravis in mid-2027, subject to regulatory feedback, evaluating dosing every 4 and 8 weeks.
-
5
VRDN-008 has not demonstrated clinical benefit in thyroid eye disease, and Viridian has not announced a TED-specific development program for the drug.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.